Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer.
ICI treatment duration
long-term responders
nivolumab
non-small cell lung cancer
pembrolizumab
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
03
2023
accepted:
31
07
2023
medline:
18
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
The optimal duration of immune checkpoint inhibitor (ICI) treatment for patients with advanced non-small cell lung cancer (NSCLC) remains to be determined. Treatment durations in cornerstone phase 3 clinical trials vary between a fixed 2-year duration and pursuit until disease progression. Clinical practices may thus differ according to the attending physician. Here we provide real-world data about treatment decisions at 2 years, with subsequent clinical outcomes. This multicentric observational study included patients with advanced NSCLC whose disease was controlled after 2 years of pembrolizumab or nivolumab. The primary outcome was the decision to discontinue ICI treatment or not, along with factors motivating this decision. Secondary outcomes included progression-free survival (PFS) (according to treatment continuation or not) and adverse events. A total of 91 patients were included, of which 60 (66%) had been pre-treated. The programmed death-ligand 1 expression level was ⩾50% in 43 patients (47%). In 61 patients (67%), ICI was continued after 2 years of treatment. This decision was significantly associated with the care center ( The decision to continue ICI or not after 2 years of treatment depends mainly on the care center and does not seem to impact survival. Larger, randomized data sets are required to confirm this result.
Sections du résumé
Background
UNASSIGNED
The optimal duration of immune checkpoint inhibitor (ICI) treatment for patients with advanced non-small cell lung cancer (NSCLC) remains to be determined. Treatment durations in cornerstone phase 3 clinical trials vary between a fixed 2-year duration and pursuit until disease progression. Clinical practices may thus differ according to the attending physician.
Objectives
UNASSIGNED
Here we provide real-world data about treatment decisions at 2 years, with subsequent clinical outcomes.
Design and Methods
UNASSIGNED
This multicentric observational study included patients with advanced NSCLC whose disease was controlled after 2 years of pembrolizumab or nivolumab. The primary outcome was the decision to discontinue ICI treatment or not, along with factors motivating this decision. Secondary outcomes included progression-free survival (PFS) (according to treatment continuation or not) and adverse events.
Results
UNASSIGNED
A total of 91 patients were included, of which 60 (66%) had been pre-treated. The programmed death-ligand 1 expression level was ⩾50% in 43 patients (47%). In 61 patients (67%), ICI was continued after 2 years of treatment. This decision was significantly associated with the care center (
Conclusion
UNASSIGNED
The decision to continue ICI or not after 2 years of treatment depends mainly on the care center and does not seem to impact survival. Larger, randomized data sets are required to confirm this result.
Identifiants
pubmed: 37720494
doi: 10.1177/17588359231195600
pii: 10.1177_17588359231195600
pmc: PMC10501064
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359231195600Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
AC reports grants to institution from Meck and Roche; consulting fees from Novartis; honoraria from Sanofi, Pfizer, Novartis, Takeda, Amgen; payment for expert testimony from Pfizer, Takeda, Novartis, Janssen, Roche, Abbvie; support for attending meetings and/or travel from Novartis and Takeda; consulting or advisory role with Novartis and InhaTarget. CG declares receiving support for attending meetings and/or travel from Pfizer and Novartis. The other authors declare that there is no conflict of interest.
Références
J Clin Oncol. 2017 Dec 10;35(35):3924-3933
pubmed: 29023213
Lancet Respir Med. 2020 Sep;8(9):895-904
pubmed: 32199466
Anticancer Res. 2019 Jul;39(7):3961-3965
pubmed: 31262928
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Cancer Immunol Immunother. 2019 Mar;68(3):341-352
pubmed: 30725206
J Clin Oncol. 2020 May 10;38(14):1580-1590
pubmed: 32078391
Lung Cancer. 2013 Jan;79(1):73-6
pubmed: 23083516
Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221
pubmed: 32474768
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Ann Oncol. 2020 Nov;31(11):1435-1448
pubmed: 32763453
JAMA Oncol. 2018 Mar 01;4(3):374-378
pubmed: 28975219
Cancer Immunol Res. 2016 Mar;4(3):194-203
pubmed: 26787823
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Clin Oncol. 2021 Mar 1;39(7):723-733
pubmed: 33449799
Lancet Oncol. 2016 Dec;17(12):e560-e567
pubmed: 27924754
Ann Oncol. 2023 Apr;34(4):358-376
pubmed: 36669645
JTO Clin Res Rep. 2022 Mar 19;3(4):100309
pubmed: 35434666
Lung Cancer. 2020 Dec;150:159-163
pubmed: 33171404
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Cancers (Basel). 2021 Sep 10;13(18):
pubmed: 34572771
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
Rev Mal Respir. 2014 Nov;31(9):805-16
pubmed: 25433585
J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485
pubmed: 30506406
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
JTO Clin Res Rep. 2021 Jan 19;2(5):100147
pubmed: 34590015
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
J Clin Oncol. 2020 Nov 20;38(33):3863-3873
pubmed: 32910710
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
JTO Clin Res Rep. 2020 Feb 11;1(1):100008
pubmed: 34589912
ESMO Open. 2018 Oct 02;3(6):e000406
pubmed: 30305940
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
J Clin Oncol. 2021 Jul 20;39(21):2339-2349
pubmed: 33872070
JAMA Oncol. 2016 Jan;2(1):46-54
pubmed: 26562159
J Clin Oncol. 2018 Jun 10;36(17):1675-1684
pubmed: 29570421
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Cancer. 2022 Feb 15;128(4):778-787
pubmed: 34705268
J Thorac Oncol. 2021 Oct;16(10):1718-1732
pubmed: 34048946